Agile contraceptive patch to undergo 10-month US FDA review
This article was originally published in Scrip
Executive Summary
Privately held Agile Therapeutics' new drug application for its once-weekly, low-dose contraceptive patch, AG200-15, was accepted for a standard 10-month review by the US FDA, with the agency likely making a decision by the first quarter of next year